138 related articles for article (PubMed ID: 21631148)
1. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.
Poleszczuk J; Bodnar M; Foryś U
Math Biosci Eng; 2011 Apr; 8(2):591-603. PubMed ID: 21631148
[TBL] [Abstract][Full Text] [Related]
2. Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis.
Schättler H; Ledzewicz U; Cardwell B
Math Biosci Eng; 2011 Apr; 8(2):355-69. PubMed ID: 21631134
[TBL] [Abstract][Full Text] [Related]
3. Optimal and suboptimal protocols for a mathematical model for tumor anti-angiogenesis in combination with chemotherapy.
Ledzewicz U; Maurer H; Schättler H
Math Biosci Eng; 2011 Apr; 8(2):307-23. PubMed ID: 21631132
[TBL] [Abstract][Full Text] [Related]
4. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999).
d'Onofrio A; Gandolfi A
Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652
[TBL] [Abstract][Full Text] [Related]
5. Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment.
Ledzewicz U; Marriott J; Maurer H; Schättler H
Math Med Biol; 2010 Jun; 27(2):157-79. PubMed ID: 20513667
[TBL] [Abstract][Full Text] [Related]
6. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis.
Ledzewicz U; Schättler H
J Theor Biol; 2008 May; 252(2):295-312. PubMed ID: 18371982
[TBL] [Abstract][Full Text] [Related]
7. Optimization of vascular-targeting drugs in a computational model of tumor growth.
Gevertz J
Phys Rev E Stat Nonlin Soft Matter Phys; 2012 Apr; 85(4 Pt 1):041914. PubMed ID: 22680505
[TBL] [Abstract][Full Text] [Related]
8. Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy.
Yonucu S; Yιlmaz D; Phipps C; Unlu MB; Kohandel M
PLoS Comput Biol; 2017 Sep; 13(9):e1005724. PubMed ID: 28922358
[TBL] [Abstract][Full Text] [Related]
9. Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles.
Sinek J; Frieboes H; Zheng X; Cristini V
Biomed Microdevices; 2004 Dec; 6(4):297-309. PubMed ID: 15548877
[TBL] [Abstract][Full Text] [Related]
10. Optimal scheduling of radiotherapy and angiogenic inhibitors.
Ergun A; Camphausen K; Wein LM
Bull Math Biol; 2003 May; 65(3):407-24. PubMed ID: 12749532
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Kerbel RS
Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
[TBL] [Abstract][Full Text] [Related]
12. Model-based angiogenic inhibition of tumor growth using modern robust control method.
Kovács L; Szeles A; Sápi J; Drexler DA; Rudas I; Harmati I; Sápi Z
Comput Methods Programs Biomed; 2014 May; 114(3):e98-110. PubMed ID: 24472366
[TBL] [Abstract][Full Text] [Related]
13. Comparison of simple models of periodic protocols for combined anticancer therapy.
Dołbniak M; Swierniak A
Comput Math Methods Med; 2013; 2013():567213. PubMed ID: 23653666
[TBL] [Abstract][Full Text] [Related]
14. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy.
D'Onofrio A; Gandolfi A
Math Med Biol; 2009 Mar; 26(1):63-95. PubMed ID: 19033598
[TBL] [Abstract][Full Text] [Related]
15. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling.
Bodzioch M; Bajger P; Foryś U
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2281-2299. PubMed ID: 34050795
[TBL] [Abstract][Full Text] [Related]
18. [Rationale of antiangiogenic therapy].
Tímár J; Paku S; Tóvári J; Döme B
Magy Onkol; 2006; 50(2):141-51. PubMed ID: 16888678
[TBL] [Abstract][Full Text] [Related]
19. Mathematical modelling of toxicity-related trade-offs in metronomic chemotherapy.
Majumder D; Mukherjee A
IET Syst Biol; 2007 Sep; 1(5):298-305. PubMed ID: 17907679
[TBL] [Abstract][Full Text] [Related]
20. Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy.
Schättler H; Ledzewicz U; Amini B
J Math Biol; 2016 Apr; 72(5):1255-80. PubMed ID: 26089097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
